Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
The Medicines Patent Pool (MPP) broadens collaboration with Gilead Sciences: Signs licence for Phase III medicine tenofovir alafenamide (TAF)

The licence will allow manufacturers in India and China to develop generic versions of TAF for 112 countries that are home to more than 92% of people living with HIV in the developing world.

Published
10 hours ago
From
Medicines Patent Pool
Novel techniques probed in cure research

Two presentations at the 20th International AIDS Conference (AIDS 2014) in Melbourne described new pathways being explored in the search for either a permanent cure for HIV

Published
22 July 2014
By
Gus Cairns
HIV, HCV and TB Pipeline Report

Drugs, diagnostics, vaccines, preventive technologies, research towards a cure, and immune-based and gene therapies in development.

Published
21 July 2014
From
Treatment Action Group & i-Base
Therapy with newer, safer antiretrovirals an option for the majority of HIV-positive patients

The majority of people taking antiretroviral therapy (ART) that includes drugs associated with long-term side-effects may have the option of switching to a novel regimen

Published
11 July 2014
By
Michael Carter
Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV

ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine) for the treatment of HIV infection in adults and adolescents aged 12 years and older and weighing at least 40kg.

Published
30 June 2014
From
Viiv Healthcare press release
Dolutegravir in HIV-1 infection: Added benefit in adult patients

The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.

Published
19 June 2014
From
Science Daily
Glaxo's ViiV Joins J&J's Janssen to Develop Single-Pill HIV Drug

Glaxo’s majority-owned ViiV Healthcare venture is collaborating with Johnson & Johnson’s Janssen unit to test a pill combining ViiV’s Tivicay with Janssen’s Edurant, ViiV said today in a statement. Trials are expected to begin next year, the Brentford, U.K.-based company said.

Published
13 June 2014
From
Bloomberg
Paper explores new theory on spread of HIV by "popular" cells

"Popular" cells - could there really be such a thing? According to a new opinion paper published in PLoS Pathogens, the human body may contain cells that have more contact with other cells and could be "superspreaders" of the HIV virus.

Published
11 June 2014
From
HIV / AIDS News From Medical News Today
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily formulation of raltegravir (Isentress)

Merck (MSD) today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Raltegravir combines high potency with low toxicity but its more widespread use has been held back by its needing to be taken twice a day.

Published
06 June 2014
From
Merck
Dolutegravir in HIV-1 infection: added benefit in adult patients

German health technology assessment concludes that the dossier compiled by the drug manufacturer provided proof of a considerable added benefit in adults without pretreatment and an indication of a minor added benefit in pretreated adults who require integrase inhibitors (INIs) (i. e. whose treatment should include an INI). These patients have fewer side effects with the new drug than with the respective comparator therapy.

Published
23 May 2014
From
IQWIG
← First12345...77Next →

Filter by country